More Batches of Moderna COVID-19 Shots Shipped Amid Reports of Shortages
While supplies of the updated Pfizer booster shot appear to be plentiful, some pharmacies have reported not having enough of the updated Moderna vaccine.
While supplies of the updated Pfizer booster shot appear to be plentiful, some pharmacies have reported not having enough of the updated Moderna vaccine.
The guideline authors strongly recommend against the use of sotrovimab and casirivimab-imdevimab for patients with COVID-19.
Monthly COVID-19-associated hospitalization rates ranged from 3.5 times to 17.7 times higher in unvaccinated persons than vaccinated persons, regardless of booster dose status.
The FDA has authorized the bivalent Moderna and Pfizer-BioNTech COVID-19 Vaccines as a single booster dose at least 2 months following the primary or booster vaccination.
The risk of myocarditis was generally greater after SARS-CoV-2 infection than after COVID-19 vaccination.
Seroconversion rates were low for patients receiving anti-CD20 therapy, CAR T-cell therapy, and transplants, as well as CLL patients taking ibrutinib.
The incidence of myocarditis appeared to be higher with the Moderna vaccine than with the Pfizer-BioNTech vaccine.
The Biden administration is working on contracts for the reformulated booster doses.
Researchers observed a shorter length of stay and less intensive care use with a remote patient monitoring program.
Third and fourth doses were tied to significantly increased anti-S IgG titers in older adults, but the optimal timing of additional doses was not known.